Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 4:42 PM
Ignite Modification Date:
2025-12-24 @ 4:42 PM
NCT ID:
NCT03274466
Eligibility Criteria:
Pre-operative Inclusion Criteria:
The subject:
* is at least 22 years of age on the date of informed consent
* is able to provide their own informed consent
* requires a TKA revision defined as one of the following:
1. a one-stage aseptic revision procedure
2. a one-stage septic exchange procedure (requiring removal of all hardware) for acute postoperative infection
3. removal of cement spacer and re-implantation procedure
4. open reduction and internal fixation of peri-prosthetic fractures
* has one or more of the following:
1. a body mass index (BMI) greater than 35 kg/m2
2. a requirement for the use of blood thinners other than acetylsalicylic acid (ASA) after surgery
3. history of or current peripheral vascular disease
4. the presence of lymphedema in the operative limb
5. insulin-dependent diabetes mellitus
6. current tobacco use or previous history of smoking and quitting within the past 30 days
7. a history of prior infection of the operative site
8. current use of immunomodulators or steroids
9. current or history of cancer or hematological malignancy (excluding localized skin cancer)
10. rheumatoid arthritis
11. current renal failure or dialysis
12. malnutrition as determined by the investigator
13. liver disease as determined by the investigator
14. status post solid organ transplant
15. HIV
* is willing and able to return for all scheduled study visits
* if female, has a negative urine or serum pregnancy test at screening and day of revision surgery. Women who have had surgical sterilization by a medically accepted method such as tubal ligation, hysterectomy, or oophorectomy or are post-menopausal, defined as not having menstruation for \>= 12 months will be excluded from requiring this test.
Intra-operative Inclusion Criteria:
The subject:
* continues to meet all pre-operative inclusion criteria
* has undergone a TKA revision resulting in a closed surgical incision
Pre-operative Exclusion Criteria:
The subject:
* is pregnant or lactating
* will undergo a bilateral TKA within the same operative visit
* will undergo a bilateral TKA in which the first TKA surgery is on the knee selected for study
* will undergo a staged bilateral TKA in which the TKA revision surgery for the knee under study occurs within 30 days of the first TKA procedure
* was previously randomized in this protocol
* has a systemic active infection at the time of revision not including chronic viral infections such as HIV or hepatitis
* has a remote-site skin infection at the time of revision
* was tattooed on the area of the incision within 30 days prior to randomization
* has known sensitivity to the study product components (drape and/or dressing materials in direct contact with the closed incision or skin)
* has known sensitivity to silver
* is currently enrolled in another investigational trial that requires additional interventions
* is planned to be enrolled in another investigational trial that requires additional interventions at any time during the study
* has localized skin cancer around the incision site
Intra-operative Exclusion Criteria:
The subject:
* is found to meet any of the pre-operative exclusion criteria
* has a surgical incision that precludes placement of dressing
* has a TKA revision resulting in a muscle flap
* has a TKA revision resulting in the placement of a spacer
* has an incision drainage and debridement procedure only
* has a surgical incision closed with skin glue
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
22 Years
Study:
NCT03274466
Study Brief:
Protocol Section:
NCT03274466